Letícia de Souza Figueiredo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Letícia de Souza Figueiredo has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Everardo Magalhães Carneiro
Universidade Estadual de Campinas (UNICAMP)
2 shared publications Israelle N. Freitas
Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, SP, Brazil
2 shared publications- Joel A. DA Silva Júnior
Universidade Estadual de Campinas, Brazil
2 shared publications Juliana N. Silva
Laboratório de Fisiopatologia, Divisão de Pesquisa Integrada em Produtos Bioativos e Biociências (DPBio), Polo Novo Cavaleiros, Universidade Federal do Rio de Janeiro, Campus UFRJ-Macaé, Macaé, RJ, Brazil
2 shared publicationsKênia M. Oliveira
Laboratório de Fisiopatologia, Divisão de Pesquisa Integrada em Produtos Bioativos e Biociências (DPBio), Polo Novo Cavaleiros, Universidade Federal do Rio de Janeiro, Campus UFRJ-Macaé, Macaé, RJ, Brazil
2 shared publications- Rosane Aparecida Ribeiro
Universidade Estadual de Ponta Grossa (UEPG)
2 shared publications
Latest Publications
- 30 October 2026
- Published by Wiley in The Journal of Physiology
Combined time‐restricted feeding and resistance training enhance tirzepatide‐induced improvements in adiposity and whole‐body insulin sensitivity in female mice
Tirzepatide is a dual agonist of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptors with potent effects on body weight regulation, glucose homeostasis and metabolic health. However, its interaction with dietary and exercise interventions as well as its impact on obesity and hepatic metabolic pathways, particularly in females, remain unclear. Here, we tested whether tirzepatide, alone or combined with time‐restricted feeding (TRF) or resistance training, modulates energy balance, strength performance, adipose tissue remodelling, insulin sensitivity and hepatic lipid accumulation in female mice. Female Swiss mice after 10 weeks of obesity induction were treated with tirzepatide, TRF or resistance training for 8 weeks. Tirzepatide was administered subcutaneously using a dose‐escalation protocol. TRF consisted of a 12 h feeding window, and resistance training was performed as stair climbing on alternating days. Body weight, caloric intake and feed efficiency were monitored longitudinally. Glucose homeostasis was assessed by intraperitoneal glucose and insulin tolerance tests. Adipose depots, skeletal muscle and liver mass were quantified, and hepatic lipid accumulation was evaluated by histology and RT‐qPCR of lipogenic metabolism genes. Tirzepatide reduced body weight gain and feed efficiency, consistent with a negative energy balance. When combined with TRF and resistance training, tirzepatide accelerated weight loss, and the addition of resistance training further enhanced this effect, bringing body weight close to control levels. These effects were associated with reduced adipose mass and adipocyte hypertrophy, indicating improved adipose tissue remodelling. Resistance training improved strength performance and increased skeletal muscle mass. Tirzepatide combined with TRF, with or without resistance training, improved glucose tolerance in female mice. All interventions reduced hepatic lipid accumulation. Collectively, tirzepatide, particularly in combination with TRF and resistance training, exerts enhanced metabolic benefits on obesity, insulin sensitivity and metabolic regulation in female mice. image Key points: Tirzepatide combined with time‐restricted feeding and resistance training produced greater reductions in body weight and adiposity in obese female mice. Combined interventions improved whole‐body insulin sensitivity more effectively than isolated strategies. Resistance training preserved skeletal muscle mass during tirzepatide‐induced weight loss. All interventions similarly reduced hepatic lipid accumulation and lipogenic gene expression. Tirzepatide‐based therapies enhanced systemic metabolic health without additional hepatic benefits from combined interventions.
- 30 October 2026
- Published by Wiley in The Journal of Physiology
Combined time‐restricted feeding and resistance training enhance tirzepatide‐induced improvements in adiposity and whole‐body insulin sensitivity in female mice
Tirzepatide is a dual agonist of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptors with potent effects on body weight regulation, glucose homeostasis and metabolic health. However, its interaction with dietary and exercise interventions as well as its impact on obesity and hepatic metabolic pathways, particularly in females, remain unclear. Here, we tested whether tirzepatide, alone or combined with time‐restricted feeding (TRF) or resistance training, modulates energy balance, strength performance, adipose tissue remodelling, insulin sensitivity and hepatic lipid accumulation in female mice. Female Swiss mice after 10 weeks of obesity induction were treated with tirzepatide, TRF or resistance training for 8 weeks. Tirzepatide was administered subcutaneously using a dose‐escalation protocol. TRF consisted of a 12 h feeding window, and resistance training was performed as stair climbing on alternating days. Body weight, caloric intake and feed efficiency were monitored longitudinally. Glucose homeostasis was assessed by intraperitoneal glucose and insulin tolerance tests. Adipose depots, skeletal muscle and liver mass were quantified, and hepatic lipid accumulation was evaluated by histology and RT‐qPCR of lipogenic metabolism genes. Tirzepatide reduced body weight gain and feed efficiency, consistent with a negative energy balance. When combined with TRF and resistance training, tirzepatide accelerated weight loss, and the addition of resistance training further enhanced this effect, bringing body weight close to control levels. These effects were associated with reduced adipose mass and adipocyte hypertrophy, indicating improved adipose tissue remodelling. Resistance training improved strength performance and increased skeletal muscle mass. Tirzepatide combined with TRF, with or without resistance training, improved glucose tolerance in female mice. All interventions reduced hepatic lipid accumulation. Collectively, tirzepatide, particularly in combination with TRF and resistance training, exerts enhanced metabolic benefits on obesity, insulin sensitivity and metabolic regulation in female mice. image Key points: Tirzepatide combined with time‐restricted feeding and resistance training produced greater reductions in body weight and adiposity in obese female mice. Combined interventions improved whole‐body insulin sensitivity more effectively than isolated strategies. Resistance training preserved skeletal muscle mass during tirzepatide‐induced weight loss. All interventions similarly reduced hepatic lipid accumulation and lipogenic gene expression. Tirzepatide‐based therapies enhanced systemic metabolic health without additional hepatic benefits from combined interventions.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 97 (4) , e20250004
Combined oral contraceptive administration in female mice attenuated high-fat diet-induced obesity but not hepatic inflammation or fibrosis
Combined oral contraceptives (COC)s are the contraceptive method of choice for millions of women worldwide. In this study, we aimed to investigate the effects of COC administration, composed of 17α-ethinylestradiol (EE2) and drospirenone (DRSP), on obesity, glucose tolerance, and hepatic steatosis in female mice. Eighty-day-old Swiss female mice were fed either a standard diet (SD) or a high-fat diet (HFD) and daily received, via gavage, 0.2 mL of distilled water (CTL-SD and CTL-HFD groups) with or without COC (COC-SD and COC-HFD groups) for 65 days. COC administration attenuated body weight and adiposity gains and prevented glucose intolerance induced by HFD in COC-HFD females. These effects were accompanied by the upregulation of Prdm16 and Ucp-1 genes in the brown adipose tissue (BAT) of COC-HFD mice. These females also exhibited a lower hepatic steatosis score than CTL-HFD mice; however, their liver parenchyma showed an increased number of inflammatory foci, and up-regulation of the Il-1β gene. Thus, COC administration in female mice attenuated obesity development induced by HFD, possibly through modulation of BAT function, while the increased hepatic expression of the pro-inflammatory cytokine IL-1β suggests that COC exacerbated HFD-induced liver inflammation.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 97 (4) , e20250004
Open AccessCombined oral contraceptive administration in female mice attenuated high-fat diet-induced obesity but not hepatic inflammation or fibrosis
Combined oral contraceptives (COC)s are the contraceptive method of choice for millions of women worldwide. In this study, we aimed to investigate the effects of COC administration, composed of 17α-ethinylestradiol (EE2) and drospirenone (DRSP), on obesity, glucose tolerance, and hepatic steatosis in female mice. Eighty-day-old Swiss female mice were fed either a standard diet (SD) or a high-fat diet (HFD) and daily received, via gavage, 0.2 mL of distilled water (CTL-SD and CTL-HFD groups) with or without COC (COC-SD and COC-HFD groups) for 65 days. COC administration attenuated body weight and adiposity gains and prevented glucose intolerance induced by HFD in COC-HFD females. These effects were accompanied by the upregulation of Prdm16 and Ucp-1 genes in the brown adipose tissue (BAT) of COC-HFD mice. These females also exhibited a lower hepatic steatosis score than CTL-HFD mice; however, their liver parenchyma showed an increased number of inflammatory foci, and up-regulation of the Il-1β gene. Thus, COC administration in female mice attenuated obesity development induced by HFD, possibly through modulation of BAT function, while the increased hepatic expression of the pro-inflammatory cytokine IL-1β suggests that COC exacerbated HFD-induced liver inflammation.
- 1 September 2020
- Published by Elsevier in Life Sciences
- Vol. 256, 118012
Bisphenol-A exposure worsens hepatic steatosis in ovariectomized mice fed on a high-fat diet: Role of endoplasmic reticulum stress and fibrogenic pathways
- 1 September 2020
- Published by Elsevier in Life Sciences
- Vol. 256, 118012
Bisphenol-A exposure worsens hepatic steatosis in ovariectomized mice fed on a high-fat diet: Role of endoplasmic reticulum stress and fibrogenic pathways
- Open Access
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 92 (4) , e20201382
D-Pinitol Increases Insulin Secretion and Regulates Hepatic Lipid Metabolism in Msg-Obese Mice
D-pinitol is one of the major inositol found in plants and studies suggest its potential hypoglycemic and hypolipidemic actions in diabetic rodents. Here, we investigated the actions of D-pinitol on adiposity, and in lipid and glycemic homeostasis in monosodium glutamate (MSG)-obese mice. Swiss mice received daily subcutaneous injections of MSG [(4g/kg of body weight (BW)] or saline [1.25g/kg BW; control (CTL)] during their first five days of life. From 90-120 day-old, half of the MSG and CTL groups received 50 mg D-pinitol/kg BW/day (MPIN and CPIN groups) or vehicle (saline; MSG and CTL groups) by gavage. MSG mice displayed higher abdominal adiposity and hepatic triglycerides (TG) deposition, and increased hepatic expression of lipogenic genes (SREBP-1c, ACC-1 and FASN), but downregulation in AMPKα mRNA. MSG mice also exhibited hyperinsulinemia, islet hypersecretion and hypertrophy, glucose intolerance and insulin resistance. D-pinitol did not change adiposity, glucose intolerance, insulin resistance, but increased hepatic triglycerides (TG) content in MPIN mice, which was associated with increases in gene expressions of SREBP-1c and FASN, but reduction in AMPKα. Furthermore, D-pinitol enhanced insulin secretion in MPIN and CPIN groups. Therefore, D-pinitol enhanced glucose-induced insulin secretion, which may account to enhances hepatic lipogenesis and TG deposition in MPIN mice.
- 1 January 2020
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 92 (4) , e20201382
Open AccessD-Pinitol Increases Insulin Secretion and Regulates Hepatic Lipid Metabolism in Msg-Obese Mice
D-pinitol is one of the major inositol found in plants and studies suggest its potential hypoglycemic and hypolipidemic actions in diabetic rodents. Here, we investigated the actions of D-pinitol on adiposity, and in lipid and glycemic homeostasis in monosodium glutamate (MSG)-obese mice. Swiss mice received daily subcutaneous injections of MSG [(4g/kg of body weight (BW)] or saline [1.25g/kg BW; control (CTL)] during their first five days of life. From 90-120 day-old, half of the MSG and CTL groups received 50 mg D-pinitol/kg BW/day (MPIN and CPIN groups) or vehicle (saline; MSG and CTL groups) by gavage. MSG mice displayed higher abdominal adiposity and hepatic triglycerides (TG) deposition, and increased hepatic expression of lipogenic genes (SREBP-1c, ACC-1 and FASN), but downregulation in AMPKα mRNA. MSG mice also exhibited hyperinsulinemia, islet hypersecretion and hypertrophy, glucose intolerance and insulin resistance. D-pinitol did not change adiposity, glucose intolerance, insulin resistance, but increased hepatic triglycerides (TG) content in MPIN mice, which was associated with increases in gene expressions of SREBP-1c and FASN, but reduction in AMPKα. Furthermore, D-pinitol enhanced insulin secretion in MPIN and CPIN groups. Therefore, D-pinitol enhanced glucose-induced insulin secretion, which may account to enhances hepatic lipogenesis and TG deposition in MPIN mice.